Isabelle A.
- Country
- France
- Department
- Service des pathologies du sommei
Research Overview
- A Randomized, Double‑Blind, Placebo‑Controlled Study of TAK‑360 for Safety, Tolerability, and Efficacy in Adults with Narcolepsy Type 1 (Cataplexy)
- Chronobiological Intervention with Melatonin and Light Therapy in Idiopathic Hypersomnia: A Randomized, Double-Blind, Placebo-Controlled Trial
- Evaluation of Long-term Safety and Tolerability of TAK-861 in Patients with Narcolepsy Type 1
Data & Insights
Has run more than one trial at 31 of 49 partner sites.
Specializations
Sleep Disorders Research
This investigator specializes in the study of central disorders of hypersomnolence, with particular emphasis on therapeutic interventions for sleep-related conditions.
- Idiopathic Hypersomnia (IH)
- Narcolepsy Type 1 with Cataplexy
The research encompasses evaluation of novel therapeutic compounds and treatment approaches for excessive daytime sleepiness.
Therapeutic Innovation
The investigator focuses on evaluating emerging treatments including orexin receptor antagonists and chronobiotherapy approaches.
- Novel pharmaceutical compounds
- Light therapy interventions
- Melatonin-based treatments
Research activities center on both short-term efficacy and long-term safety assessments of therapeutic interventions.
Clinical Assessment
The investigator employs specialized clinical measurement tools to evaluate treatment outcomes in sleep disorders.
- Epworth Sleepiness Scale (ESS)
- Idiopathic Hypersomnia Severity Scale (IHSS)
- Safety and tolerability assessments
Research methodology incorporates validated assessment scales for sleep disorder symptomatology.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.